Duyuru • Jul 03

ICON Public Limited Company (NasdaqGS:ICLR) completed the acquisition of PRA Health Sciences, Inc. (NasdaqGS:PRAH).

ICON Public Limited Company (NasdaqGS:ICLR) entered into an agreement to acquire PRA Health Sciences, Inc. (NasdaqGS:PRAH) for $10.9 billion on February 24, 2021. ICON will acquire PRA in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. Upon completion of the transaction, PRA shareholders will own approximately 34% of the shares of the combined company and ICON shareholders will own approximately 66%. ICON intends to fund the cash portion of the transaction consideration through a combination of cash on hand and fully committed debt financing from Citi. ICON entered into a commitment letter with Citigroup Global Markets Inc. and certain other financial institutions to provide to ICON a senior secured revolving credit facility in an aggregate principal amount of up to $300 million and a senior secured bridge loan facility in an aggregate principal amount of up to $6,060 million to, among other things, fund (i) cash consideration in connection with the merger, (ii) repayment of certain existing indebtedness and (iii) fees and expenses in connection with the foregoing. ICON will finance the transaction from a notes offering of $500 million. PRA will be obligated to pay to ICON a termination fee of $277 million. ICON will be obligated to pay to PRA a termination fee of $388 million. Steve Cutler, Chief Executive Officer of ICON plc, will serve as Chief Executive Officer of the combined company and Brendan Brennan, Chief Financial Officer of ICON plc, will serve as Chief Financial Officer. Ciaran Murray will serve as the Chairman of the Board of Directors. Current PRA Chairman and Chief Executive Officer, Colin Shannon will join the board post the closing of the transaction along with one additional board member from PRA and to nominate such two new directors for re-election to the ICON board at such next annual general meeting of ICON. ICON and PRA expect that, after giving effect to such appointments, ICON’s board of directors will comprise one executive director and eleven outside directors. ICON’s constitution provides that, unless otherwise determined by ICON at a general meeting, the number of directors shall not be more than fifteen nor fewer than three. ICON’s board of directors comprises one executive director and nine outside or non-executive directors at the date of this joint proxy statement/prospectus. The combined company will be headquartered in Dublin, Ireland. The transaction is subject to regulatory and shareholder of ICON and PRA approval, the receipt of antitrust clearance in the United States, Austria, Germany and Russia, and to approval of foreign direct investment in each of Austria, France, Germany, Italy and New Zealand. In the United States, ICON and PRA each filed a notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR Act, which is referred to as an HSR notification, with the Federal Trade Commission, or FTC, and the Department of Justice, or DOJ, the ICON Ordinary Shares to be issued in the Merger having been approved for listing on the Nasdaq, obtainment of certain consents, approvals and other authorizations of governmental entities free of any burdensome condition, the effectiveness of the registration statement of which this joint proxy statement/prospectus and satisfaction or waiver of the other customary closing conditions. The transaction is not subject to a financing condition. The ICON board of directors unanimously recommends that ICON shareholders vote “FOR” each of the proposals to be considered at the ICON EGM. The PRA board of directors unanimously recommends that PRA stockholders vote “FOR” each of the proposals to be considered at the PRA stockholder meeting. The transaction has been unanimously approved by both Boards of Directors. German Federal Cartel Office has provided antitrust clearance to the transaction on April 12, 2021. The waiting period under the HSR Act with respect to the filed notifications expired on April 14, 2021. Approval was received with respect to antitrust filings in Austria on April 17, 2021. Approval with respect to the New Zealand filing was received on April 19, 2021, and approvals with respect to the German and Italian foreign direct investment filings were received on April 22, 2021. As of May 13, 2021, the transaction is approved by Federal Antimonopoly Service of Russia (FAS). With FAS approval, all antitrust approvals necessary for the closing of the transaction have been received. On June 15, 2021, the shareholders of PRA Health Sciences approved the transaction. On June 15, 2021, the shareholders of ICON approved the transaction. The transaction is anticipated to close during third quarter of 2021. As of April 26, 2021, the transaction will be completed in July 2021. As of May 17, 2021, the transaction is expected to complete on July 1, 2021. The transaction is anticipated to be highly accretive delivering double-digit accretion in the first full year and growing to 20%+ thereafter, driven by growth momentum, estimated annual run-rate cost synergies of $150 million, and the combined effective tax rate decreasing to 14%, both to be realized in approximately 4 years. William M. Hartnett, Kimberly C. Petillo-Décossard, Ross E. Sturman, Craig Horowitz, Adam Dworkin, Glenn Waldrip, Mark Gelman, Elai Katz, Brock Bosson and Lauren Rackow of Cahill Gordon & Reindel serving as legal counsel to ICON plc. Krishna Veeraraghavan, Laura C. Turano, Caith Kushner, Greg Liu, Suhan Shim, Mikhel Schecter, Rick Rule, Andrew Forman, Steven Herzog, Peter Jaffe, Rachel Fiorill, Jonathan Ashtor, Robert Holo, Marta Kelly, Richard Elliott and William O'Brien of Paul, Weiss, Rifkind, Wharton & Garrison LLP serving as legal counsel to PRA. Cian McCourt, Fintan Clancy, Cian Beecher, Colin Kavanagh, Olivia Mullooly and Patrick Horan of Arthur Cox LLP acted as legal advisors for PRA. Mark Ward, Berni Hosty, Richard Marron, Keavy Ryan, Seamus O 'Croinin, Alan McCarthy, Anna Marie Curran and Paul Fahy of A&L Goodbody acted as legal advisors for ICON. Matthew M. Friestedt of Sullivan & Cromwell LLP acted as legal advisors to PRA. MacKenzie Partners, Inc. acted as the proxy solicitation agent for PRA with a fee of approximately $50,000 for the services rendered. Georgeson LLC, acted as the proxy solicitation agent for ICON with a fee of approximately $20,000, plus costs and expenses. BofA Securities, Inc. acted as fairness opinion provider and financial advisor to PRA with a fee of approximately $30 million, $2 million of which was payable upon delivery of its opinion and the remainder of which is payable upon the closing of the merger. UBS Securities LLC acted as fairness opinion provider and as financial advisor to PRA with a fee of approximately $30 million, $2 million of which became payable upon delivery of UBS’ opinion and remainder of which is contingent upon consummation of the merger. Centerview Partners is acting as lead financial advisor with Citi providing additional financial advisory services to ICON. Centerview Partners LLC acted as fairness opinion provider to ICON with an aggregate fee of $30 million, $5 million of which was payable upon the rendering of Centerview’s opinion and $25 million of which is payable contingent upon consummation of the transaction. Fabian Badtke, Jens Peter Schmidt, Stefan Weber, Philipp Studt, Artem Kara, Sascha Giller, Edina Schweizer and Jörg Menzer of Noerr; Tom Usher and Sophie Chesterton of Macfarlanes LLP; Forrest Alogna and Maxime Wach of Darrois Villey Maillot Brochier; Francesco Salerno and Federico Macchi of Gianni, Origoni, Grippo, Cappelli & Partners and Christian Mayer, Moritz am Ende and Elisabeth Wielinger of Schima Mayer Starlinger Rechtsanwälte GmbH acted as legal advisors for ICON. ICON Public Limited Company (NasdaqGS:ICLR) completed the acquisition of PRA Health Sciences, Inc. (NasdaqGS:PRAH) on July 1, 2021. As part of closing ICON issued $500 million notes in a private offering and proceeds will be used to fund the cash consideration payable by ICON, refinance and repay certain existing indebtedness of ICON, its subsidiaries and PRA and pay fees and expenses related to the merger.

Life Sciences Sektör Büyümesi	26.83%
Gelir büyüme oranı	17.55%
Özkaynak getirisi	6.42%
Net Marj	7.40%
Sonraki Kazanç Güncellemesi	28 May 2026

Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 25	8,103	599	759
30 Jun 25	8,090	794	768
31 Mar 25	8,193	758	756
31 Dec 24	8,282	791	736
30 Sep 24	8,307	748	777
30 Jun 24	8,332	714	755
31 Mar 24	8,232	683	754
31 Dec 23	8,120	612	776
30 Sep 23	8,016	513	811
30 Jun 23	7,903	510	790
31 Mar 23	7,818	510	790
31 Dec 22	7,741	505	783
30 Sep 22	7,665	464	758
30 Jun 22	7,588	210	871
31 Mar 22	6,524	168	771
31 Dec 21	5,481	153	662
30 Sep 21	4,356	178	547
30 Jun 21	3,191	364	350
31 Mar 21	2,940	338	344
31 Dec 20	2,797	328	342
30 Sep 20	2,762	322	343
30 Jun 20	2,771	324	345
31 Mar 20	2,846	368	344
31 Dec 19	2,806	369	333
30 Sep 19	2,759	362	336
30 Jun 19	2,704	353	330
31 Mar 19	2,651	333	328
31 Dec 18	2,596	323	326
30 Sep 18	2,372	306	321
30 Jun 18	2,157	295	320
31 Mar 18	1,947	288	326
31 Dec 17	1,758	281	324
30 Sep 17	1,738	285	331
30 Jun 17	1,718	274	333
31 Mar 17	1,698	271	326
31 Dec 16	1,666	262	326
30 Sep 16	1,635	251	326
30 Jun 16	1,609	249	327
31 Mar 16	1,587	247	328
31 Dec 15	1,575	240	327
30 Sep 15	1,562	221	329
30 Jun 15	1,555	210	331

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/26 16:58
Gün Sonu Hisse Fiyatı	2026/05/26 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

Analist	Kurum
Eric Coldwell	Baird
Douglas Tsao	Barclays
Luke Sergott	Barclays

ICON Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

ICON Public Limited Company to Report Q4, 2025 Results on May 27, 2026

ICON Public Limited Company to Report Q4, 2025 Results on Apr 30, 2026

Icon plc Reports Goodwill Impairment for the Third Quarter Ended September 30, 2025

ICON Public Limited Company to Report Q3, 2025 Results on Oct 22, 2025

ICON Public Limited Company to Report Q2, 2025 Results on Jul 23, 2025

ICON Public Limited Company to Report Q1, 2025 Results on Apr 30, 2025

Recent updates

ICON Public Limited Company to Report Q4, 2025 Results on May 27, 2026

ICON Public Limited Company announced delayed 20-F filing

An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC.

ICON Public Limited Company to Report Q4, 2025 Results on Apr 30, 2026

ICON plc Releases Findings from Two Biotech Sector Survey

Icon plc Announces Results of Its Latest Industry Survey

Icon plc Reports Goodwill Impairment for the Third Quarter Ended September 30, 2025

ICON Public Limited Company to Report Q3, 2025 Results on Oct 22, 2025

ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD)

ICON plc Appoints Barry Balfe to the Board

ICON Public Limited Company Updates Earnings Guidance for Full Year 2025

ICON Public Limited Company to Report Q2, 2025 Results on Jul 23, 2025

ICON Public Limited Company, Annual General Meeting, Jul 22, 2025

Icon Public Limited Company Updates Earnings Guidance for Full Year 2025

ICON Public Limited Company to Report Q1, 2025 Results on Apr 30, 2025

ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025

ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $750 million worth of its shares.

Robbins LLP Announces Class Action Lawsuit Against ICON PLC

Icon Portfolio of Ai Tools Drives Clinical Trial Efficiencies

ICON Public Limited Company to Report Q4, 2024 Results on Feb 19, 2025

ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025

Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative Disorders

ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer

ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares.

Third quarter 2024 earnings released: EPS: US$2.38 (vs US$1.99 in 3Q 2023)

ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024

ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024

ICON plc Announces Chief Financial Officer Changes

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$1.78 (vs US$1.41 in 2Q 2023)

ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024

ICON Public Limited Company Announces Board Changes

ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024

ICON Public Limited Company, Annual General Meeting, Jul 23, 2024

ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024

Now 21% undervalued

First quarter 2024 earnings released: EPS: US$2.27 (vs US$1.43 in 1Q 2023)

Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024

ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: US$7.46 (vs US$6.20 in FY 2022)

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

Now 21% undervalued

ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024

ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024

Third quarter 2023 earnings released: EPS: US$1.99 (vs US$1.96 in 3Q 2022)

ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.

ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023

ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution

ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial

Second quarter 2023 earnings released: EPS: US$1.41 (vs US$1.42 in 2Q 2022)

ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023

ICON Public Limited Company, Annual General Meeting, Jul 25, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$1.43 (vs US$1.37 in 1Q 2022)

Now 22% undervalued

Full year 2022 earnings released: EPS: US$6.20 (vs US$2.28 in FY 2021)

ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023

Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$1.96 (vs US$1.17 loss in 3Q 2021)

ICON Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$1.40 in 2Q 2021)

Icon Public Limited Company Revises Earnings Guidance for the Year 2022

ICON Public Limited Company to Report Q2, 2022 Results on Jul 27, 2022

ICON Public Limited Company, Annual General Meeting, Jul 26, 2022

First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.84 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $100 million worth of its shares.

Now 21% undervalued after recent price drop